A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Leveraging a CDMO’s established platform for AAV manufacturing can significantly streamline gene therapy development.

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most ...

TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.